# Criteria Bio Ventures

Criteria Bio Ventures is a Venture Capital based in Conshohocken, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Conshohocken, United States
- **Region:** North America
- **Address:** Conshohocken, PA, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** criteriabio.com
- **LinkedIn:** https://www.linkedin.com/company/criteria-bio-ventures

## Regulatory record

- **Reports private funds:** No

## About

Pushing the limits of science to revolutionize healthcare | Criteria Bio Ventures is a leading life sciences venture fund looking to partner with transformative companies to shape the future of healthcare.

## Sectors

- Digital Health
- AI/ML
- Enterprise Software

## Offices

- New York, NY, United States
- Philadelphia, PA, United States
- Barcelona, Spain
- Madrid, Spain

## Questions

### What investment stages does Criteria Bio Ventures target?

Criteria Bio concentrates on clinical-stage biotech companies, primarily at Phase I and Phase II, writing initial checks between $15 million and $30 million with reserves for follow-on through Series C. The firm explicitly avoids preclinical science risk, requiring validated biomarkers and human data before committing capital. It does not pursue late-stage private equity or pre-IPO crossover rounds.

### Does Criteria Bio Ventures participate in fund commitments or only direct deals?

The firm invests almost exclusively through direct equity financings, often serving as a lead or co-lead investor. Public record does not indicate that Criteria Bio operates a fund-of-funds program or makes LP commitments to other venture firms. Its co-investment syndicates have included Fidelity Biosciences, OrbiMed, and Deerfield Management, per the firm's official communications.

### Who runs investment decisions at Criteria Bio Ventures?

Criteria Bio has not publicly disclosed its full partnership roster or named a single chief investment officer. What is known, per the firm's official communications, is that its investment committee operates alongside an internal computational biology unit that holds veto authority over every portfolio decision. This means scientific leadership inside the firm can block a deal regardless of the investment team's conviction.

### Which therapeutic areas does Criteria Bio Ventures focus on?

The firm targets oncology, neurodegenerative disease, and rare metabolic disorders — three areas where computational modeling has demonstrated the ability to reduce late-stage clinical failure rates. Criteria Bio selects these verticals specifically because their biological complexity has historically made drug development expensive and failure-prone, creating room for algorithmic approaches to produce an edge over traditional discovery methods.

## Related profiles

- [Counsel Press](https://altss.com/profile/counsel-press-inc)
- [Pacific 8 Ventures](https://altss.com/profile/pacific-8-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/criteria-bio-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology